secwatch.observer — SEC 8-K summary
======================================

Issuer:     CRISPR Therapeutics AG (CRSP)
CIK:        0001674416
Form:       8-K
Filed at:   2026-03-11T23:59:59+00:00
Accession:  0001193125-26-101073
Event type: debt
Sentiment:  neutral
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CRISPR Therapeutics prices $550M convertible notes due 2031 at 1.125% coupon
----------------------------------------------------------------------------

- Aggregate principal amount upsized from $350M to $550M; net proceeds estimated at ~$536.3M.
- Notes mature March 1, 2031; effective coupon 1.125% (1.7308% after Swiss withholding adjustment).
- Initial conversion price ~$76.56 per share, a 45% premium over $52.80 closing price on March 10, 2026.
- Holders may convert at any time prior to maturity; company may redeem after March 6, 2029 under certain conditions.
- Proceeds for general corporate purposes; closing expected March 16, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1674416/000119312526101073/0001193125-26-101073-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1674416/000119312526101073/crsp-20260310.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-101073

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer